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Utilization and outcomes with low dose tissue plasminogen activator as
intravenous thrombolytic therapy for ischaemic stroke at Aga Khan University
Hospital, Karachi: a retrospective analysis
Masood Uz Zaman Babar1, Ammar Zaman Khan2, Haris Hakim3, Jaleed Gilani4, Mohammad Wasay5
Introduction
For the management of acute stroke, a major
breakthrough came in 1996 when the National Institute
of Neurological Disorder (NINDS) trial proved that
treatment with intravenous (IV) tissue plasminogen
activator (t-PA) within three hours of the onset of ischaemic
stroke improved clinical outcome at three months.1 Since
then, its use has been expanding, particularly in the
developed countries. In contrast, developing countries
have displayed limited progress in the management of
patients with acute stroke despite increasing incidence
of stroke and high stroke mortality rates that account for
over two-thirds of  stroke deaths worldwide.2
There are only two longitudinal studies on the utilisation
and outcome of thrombolytic therapy for acute stroke in
Pakistan to date.3,4 Both studies had small sample sizes
(21 and 13 patients respectively) along with different t-
PA dosage regimens and did not use the established
outcome parameters. The paucity of literature on the
safety and efficacy of intravenous t-PA, especially in the
Pakistani population, necessitates further investigation.
The current study was planned to determine the utilisation
and outcomes with low-dose t-PA for ischaemic stroke
thrombolysis at our hospital, and to compare the results
with those reported in the safe implementation of
thrombolysis in stroke monitoring study (SITS-MOST).5
Methods and Results
The retrospective study was conducted at the Aga Khan
University Hospital (AKUH), Karachi, and comprised
medical records from January, 2007, to October, 2016, of
all patients having received intravenous t-PA for ischaemic
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stroke thrombolysis.
After taking permission from the institutional ethics
committee, cases were identified through the International
Classification of Disease (ICD-9) coding system6 maintained
at the AKUH. Primary safety outcome variables were
symptomatic intracerebral haemorrhage (sICH) after start
of thrombolysis and mortality within 3 months as per the
modified Rankin Scale (mRS 6).7 Secondary efficacy
outcome variable was functional independence (mRS 0-
2) at 3 months. The sICH, as per SITS-MOST definition, was
def ined as  intracerebral  haemorrhage ( ICH)
(parenchymatous haemorrhage type 2) at post-treatment
scan combined with neurological deterioration leading
to an increase of 4 points or more on the National Institute
of Health Stroke Scale (NIHSS).8 ICH, as per the Cochrane
definition,9 was defined as intracerebral haemorrhage
with any drop on NIHSS. Other clinical variables of interest
included asymptomatic ICH (aICH), ICH, bleeding events
other than ICH and cerebral oedema (COED) at computed
tomography (CT) follow-up after thrombolysis treatment.
We also looked at percentage of patients cured (mRS 0),
those who had favourable outcomes (mRS 0-1), baseline
characteristics of patients with sICH, outcomes in
aetiological subgroups / Trial of 'ORG 10172' in Acute
Stroke Treatment (TOAST) classification10 and duration of
hospitalisation.
The proportion of ischaemic stroke patients receiving t-
PA was calculated and the causes summarised with the
associated frequencies. The proportions and 95%
confidence intervals (CIs) of patients with ICH and mRS
2 as well as mortality (mRS 6) was calculated for all
patients receiving t-PA. The frequency and proportion of
patients with primary and secondary outcome events, i.e.,
the incidence of sICH at CT follow-up, mortality and
functional independence was compared with SITS-MOST
results. ICH was classified on CT scans according to the
SITS-MOST definitions.
A total of 80 were identified, but 1(1.25%) case had to be
excluded as it did not have post-t-PA scan There was an
upward yearly trend towards utilisation of t-PA (Figure 1).
Baseline data, including demographics, risk factors, co-
morbids, treatments for other diseases at stroke onset for
patients at AKUH and SITS-MOST along with causes and
subtypes of stroke and time from symptom onset to t-PA
administration were noted at the outset (Table 1).
Among our cases, pre-t-PA median NIHSS of the patients
score was 12 (interquartile range [IQR]: 8-15). Of the 79
patients, 19(24%) had haemorrhages on post-treatment
imaging scans which had a statistically linear trend with
pre-t-PA NIHSS severity category on Cochran-Armitage
test of trend (p=0.015). Post-t-PA NIHSS was available for
only 9(11.4 %) patients with a median score of 9(IQR: 7-
13.5) and a median improvement of 3(IQR: 0-5). NIHSS at
discharge was available for only 2(2.5%) patients with
AKU SITS-MOST
(n=79) (n=6483)
Age(years) 62 (54-70) 68 (59-75)
Gender (female) 27 (34.2%) 2581 (39.8%)
Independence  (modified Rankin score 0-1) 79/79 (100%) 5899/6337 (93.1%)
before stroke
Hypertension 56/79 (70.9%) 3710/6318 (58.7%)
Diabetes Mellitus 24/79(30.4%) 1020/6374 (16.0%)
Ischaemic Heart Disease 19/79 (24.1%) -
Smoking 16/79 (20.3%) 2643/6114 (43.2%)
    Current 11 1474
    Previous 5 1169
Antiplatelet 26 (32.9%) 1918/6441 (29.8%)
Antihypertensive 42 (53.2%) 2983/6429 (46.4%)
Blood Glucose (mg/dl) 127.8 (102.6-176.4) 115.2 (100.8-138.6)
Weight (Kg) 70 (61 - 80) 75 (68-85)
Systolic Blood Pressure (mm Hg) 150(130-171) 150 (137-166)
Diastolic Blood Pressure (mm Hg) 81 (70-96) 81 (74-90)
Degree of neurological severity (pre t-PA NIHSS) 12 (8-15) 12 (8-17)
    Mild (NIHSS 1-7) 17/79 (21.5%) 1494 (23%)
    Moderate (NIHSS 8-14) 39/79 (49.4%) 2409 (37%)
    Severe (NIHSS 15) 23/79 (29.1%) 2571 (40%)
Previous stroke 5/79(6.3%) 643/6395 (10.1%)
Previous stroke and reduced functional status 0/79 (0 %) 80/643 (12.4%)
(mRS>1)
Cause of stroke
    Large vessel disease with substantial 5 (6.3%) 844 (13%)
     carotid stenosis
    Large vessel disease other than substantial 8 (10.1 %) 1435 (22.1%)
      carotid stenosis
    Cardiac origin 41 (51.9%) 2270 (35%)
    Lacunar stroke 4 (5.1 %) 535 (8.3%)
    Other 15 (19 %) 1171 (18.1%)
    Unknown 6 (7.6 %) 228 (3.5%)
Stroke onset to treatment time (min) 165 (135-215) 140 (115-165)
Mean delay between stroke onset and 175 (56) 136 (33)
 treatment (min)
    Treated within 90 min 3 (3.8%) 671 (10.6
    Treated within 90 - 120 min 10 (12.7 %) N/A
    Treated within 120-180 min 36 (45.6%) 4276 (66%)
    Treated within 180 - 270 min 30 (38%) N/A
Door-to-needle time (i.e. from entering the 96 (31) 68 (30)
facility to receiving treatment with alteplase) (min)
Data are median (IQR), mean (SD), or n (%). AKUS: Aga Khan University Hospital.SITS-MOST:
Safe implementation of thrombolysis in stroke monitoring study, t-PA: Tissue plasminogen
activator, NIHSS: National Institute of Health Stroke Scale, mRS.
Table-1: Baseline characteristics of patients enrolled in AKUH and SITS-MOST.
Vol. 69, No. 11, November 2019
Utilization and outcomes with low dose tissue plasminogen activator as intravenous thrombolytic....... 1707
score improvement of 1 and 3. Due to incomplete NIHSS
scores they were not included in the overall comparison
and results.
AKUH data was compared against SITS-MOST for
symptomatic ICH, as defined by the Cochrane and SITS-
MOST definition, mortality and independence for activities
of daily living (Table 2). The only mortality 1(1.3%) at AKUH
was a patient with atherothrombotic stroke according to
TOAST classification who had developed post-t-PA
symptomatic intracerebral bleed secondary to
thrombolytic treatment compared to 701(11.3%) deaths
in the SITS-MOST trial, out of which death related to
thrombolytic treatment was the outcome in 94(14%)
cases.
Also compared was three-month mRS distribution
between AKUH and SITS-MOST (Figure 2), and the
distribution and types of haemorrhages (Table 3).
The breakup of time from symptom onset to treatment
time was found to be a major contributor with a median
of 75(IQR: 40-120) minutes. The median length of hospital
stay was 4(IQR: 2-5) days.
Discussion
Studies have reported that 15 million people suffer from
stroke worldwide each year. Of these, almost five million
stroke affected people do not survive, five million are left
permanently disabled and five million recover from their
symptoms.11 The estimated annual incidence of stroke in
Pakistan is 250/100000, translating to 350,000 new cases
every year.12
In the past two decades, considerable development in
stroke care has been observed. Particularly, mortality and
dependence rates in developed countries have been
substantially reduced in patients undergoing acute
management as well as those who are in rehabilitation
and long-term care. Stroke is placed as the fifth major
cause of death after years of being the third leading cause
of death in the United States,13 suggesting an
improvement in stroke care management and related
protective measures.
Currently t-PA is the only approved medical therapy for
patients with acute ischaemic stroke. The American Heart
Association (AHA) / American Stroke Association (ASA)
recommend that t-PA at 0.9mg/kg be instituted within
AKUH SITS-MOST
Proportion Proportion
(events/total; 95% CI) (events/total; 95% CI)
sICH rates per SITS-MOST* 0 % (0/79) 1.7% (107/6444; 1.4-2.0)
sICH per Cochrane / NINDS 3.8 % (3/79; 1.3 - 10.6) 7.3% (468/6438; 6.7-7.9)
definition†
Mortality within 3 months 1.3 % (1/79; 0.2 - 6.8) 11·3% (701/6218; 10.5-12.1)
Independence (modified 50.6 % (40/79; 39.8 - 61.4) 54.8% (3362/6136; 53.5-56.0)
Rankin score 0-2) at 3 months
sICH: Symptomatic intracerebral haemorrhage. * Intracerebral haemorrhage
(parenchymatous haemorrhage type 2) at post-treatment scan combined with NIHSS drop
 4.  †NIHSS drop 1 and any haemorrhage.
Table-2: : Proportions of patients with symptomatic intracerebral haemorrhage,
mortality and independence at 3 months at AKUH and SITS-MOST.
                                                          Haemorrhages on any post treatment imaging scans
AKUH SITS-MOST
(n=79) (n=6352)
No Haemorrhage 60 (75.9 %) 5267 (82.9%)
Haemorrhagic infarct type 1 9(11.4%) 402 (6.3%)
Haemorrhagic infarct type 2 6(7.6%) 297 (4.7%)
Primary intracerebral hemorrhage type 1 3 (3.8 %) 202 (3.2%)
Primary intracerebral haemorrhage type 2 1(1.3%) 184 (2.9%)
AKUS: Aga Khan University Hospital, SITS-MOST: Safe implementation of thrombolysis
in stroke monitoring study.
Table-3: : Types of intracerebral haemorrhages detected by CT after treatment.
Figure-1: Yearly tissue plasminogen activator (t-PA) utilisation in Ischaemic
Stroke at Aga Khan University Hospital (AKUH).
Figure-2: Proportion of patients with modified Rankin score of 0-6 at 3
months in AKUS: Aga Khan Univesity Hospital (AKUH) and Safe
implementation of thrombolysis in stroke monitoring study
(SITS-MOST).
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four-and-a-half hours of symptoms onset for eligible
patients.14 International data on t-PA depicts complete
recovery in 39% patients at three months whilst a
haemorrhage rate of 7.3 per cent and mortality of 11.3
per cent have been noted as per SITS-MOST definition.5
A lower dosage (0.6mg/kg) is being used variably in the
Asian population citing comparable safety and efficacy
profiles compared to the standard dose in Western
population.15
The safety and efficacy outcomes in our patients were
comparable with that of SITS-MOST5. Standard dose
(0.9mg /kg) of IV alteplase was being used at AKUH in
2005-07 When 18/1185 (1.5%) acute stroke patients were
thrombolysed with fatal ICH seen in 3(14%) patients and
non-fatal haemorrhage in 2(10%).15 This led to a shift in
the institutional protocol towards using low-dose
(0.6mg/kg) IV alteplase for thrombolysis in ischaemic
stroke. When compared with the regional data, a
prospective study on 176 stroke patients who received
standard dose IV thrombolysis in Dubai16 reported
12(6.8%) patients developing symptomatic ICH opposed
to 0% in the current study. Two-thirds (62.1%) of patients
in the earlier study16 were of South Asian origin. Median
NIHSS was 12 (IQR: 9-15) which is similar to our results.
Another study from India17 showed haemorrhagic
transformation in 5/54 (8.8%) patients who received
standard dose IV thrombolysis. It reported no symptomatic
haemorrhage, but the definition used was not been
specified.17 Another study from India18 reported
symptomatic ICH to have occurred in 2/32 (6.25%) patients
thrombolysed with standard dose alteplase whereas
haemorrhagic conversion was noted in 3/32 (9.3%)
patients. Standard dose thrombolysis is being
administered at Shifa International hospital, Islamabad,
where 13/312 (4.1%) stroke patients received IV t-PA during
the first year of its utilisation.3 None of the patients
developed symptomatic ICH, but the definition used was
not specified.3 The Mean NIHSS was 14.85±5.289 and t-
PA was not administered in the extended window in any
of the patients.3
The mRS at three months was not consistently reported
in the regional thrombolysis studies.3,16-18 In one study,16
mRS at 3 months was available for only 71.176(40%)
patients thrombolysed. Independence (mRS 0-2) was
reported in 61(85.9%) of these 71 patients.16 It was noted
that majority of the patients who did not attain good
functional recovery might have gone back to their home
countries and were thus lost to follow-up. Safety outcome
data at 3 months (mRS) in our patients was comparable
with those reported in Western studies.5 , 19 ,2 0
Increased bleeding tendency after exposure to
thrombolytic agents has been reported in Asian
population as opposed to Western population owing to
differences in coagulation and fibrinolytic pathways.21
The rationale for using low-dose alteplase in ischaemic
stroke patients come from Japanese alteplase clinical trial
(J-ACT) in which low-dose thrombolysis was found to
have comparable efficacy and safety compared with
standard-dose thrombolysis in western population.22
Multiple studies done afterwards to establish an optimal
dosing protocol for Asian population have yielded
contradictory results which has resulted in variable dosing
regimens in different regions and, at times, in different
hospitals within the same country.23 Recently Enhanced
Control of Hypertension and Thrombolysis Stroke
(ENCHANTED) study, designed to compare the efficacy of
0.6 mg/kg alteplase with 0.9 mg/kg, could not demonstrate
non-inferiority between the two doses when assessing
disability and death as outcome with no difference
between Asians and non-Asians.24 This contradicts the J-
ACT trial and the Asian practice of using low-dose
alteplase. However, ordinal analysis of mRS scores did
show non-inferiority between the two and revealed
decreased mortality but increased disability towards the
milder end of mRS in the low-dose group. Furthermore,
there was a definitive lower risk of sICH in the low-dose
alteplase group. Considering these facts, there is still
enough evidence to consider low-dose alteplase therapy.25
The definite answer to this question, however, requires
further well-designed large-scale studies.
The utilization of t-PA remained low (1.7%) in the current
study. This trend has been seen across South Asia3,4,17
compared to Western countries (7%).26,27 The major
reasons identified for this include lack of awareness,
infrastructure constraints, safety and non-affordability as
expenses are to be borne by patients or their families.4,23
Due to non-availability of license to import t-PA from the
federal Ministry of Health, different hospitals in Pakistan
have to acquire t-PA on their own. Alteplase comes in
50mg vials only. It amounts to around US$763 per patient
whereas the per capita income in Pakistan is around
US$1,56128. Establishing a low-dose thrombolysis
regimen, if proven effective, especially in Pakistan as well
in underdeveloped parts of Asia, is of paramount
Vol. 69, No. 11, November 2019
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importance as the burden of stroke is expected to rise in
the future.29
The current study is the largest reported data from a single
centre in South Asia regarding safety and efficacy of low-
dose thrombolytic therapy in ischaemic stroke patients.
Nevertheless, the study is not without limitations as it has
a retrospective design, lacks a control arm, and still has a
relatively small sample size in the wider context.
In the light of the findings, however, it is recommended
that thrombolytic therapy should be offered to all patients
with ischemic stroke meeting the inclusion criteria and
have no contraindications. Because of increased risk of
intracerebral bleed with standard dose (0.9mg/kg) of t-
PA in our population and low usage rate, it might be
preferable to use low dose (0.6mg/kg). There is a dire need
for a large-scale study to establish definitively the efficacy
and safety of the two doses in our population. Unnecessary
delays and deviation from standard protocols should be
avoided and public awareness programmes regarding
the management of acute stroke shall be introduced.
Conclusion
Low-dose intravenous thrombolytic therapy for ischaemic
stroke patients was found to be safe and efficacious, and
yielded comparable results with those SITS-MOST.
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